Detalhe da pesquisa
1.
Ketogenic HMG-CoA lyase and its product ß-hydroxybutyrate promote pancreatic cancer progression.
EMBO J
; 41(9): e110466, 2022 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35307861
2.
Author Correction: Genomic characterization of metastatic breast cancers.
Nature
; 572(7767): E7, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31308536
3.
Genomic characterization of metastatic breast cancers.
Nature
; 569(7757): 560-564, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118521
4.
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.
Genes Dev
; 31(6): 553-566, 2017 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28404630
5.
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.
Cancer
; 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38470379
6.
The serine/threonine kinase MINK1 directly regulates the function of promigratory proteins.
J Cell Sci
; 135(17)2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35971817
7.
Mutational landscape of inflammatory breast cancer.
J Transl Med
; 22(1): 374, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38637846
8.
Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer.
Cell Commun Signal
; 22(1): 1, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167013
9.
Loss of primary cilia promotes inflammation and carcinogenesis.
EMBO Rep
; 23(12): e55687, 2022 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36281991
10.
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Mol Ther
; 31(2): 471-486, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35965411
11.
SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer.
Gut
; 72(4): 722-735, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882214
12.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Lancet Oncol
; 24(8): 892-902, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37429302
13.
Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value.
Int J Cancer
; 153(2): 407-416, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883417
14.
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
Br J Cancer
; 129(12): 1940-1948, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914801
15.
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
J Transl Med
; 21(1): 637, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726776
16.
Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.
J Transl Med
; 21(1): 408, 2023 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353806
17.
Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.
BMC Cancer
; 23(1): 69, 2023 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36670431
18.
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol
; 23(8): 1044-1054, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835135
19.
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group.
Int J Cancer
; 150(5): 825-836, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611903
20.
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Oncologist
; 27(6): 501-511, 2022 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278076